{ "@context": "https://schema.org", "@type": "Dataset", "name": "Boise Standard Entity: zeposia.bmshealthcare.jp", "url": "https://boisestandard.org/web/zeposia-bmshealthcare-jp", "identifier": "bs-1e5c8c4f", "datePublished": "2026-07-11T15:17:49.350843+00:00", "description": "Boise Standard machine-readable entity profile for zeposia.bmshealthcare.jp. Schema.org coverage graph, six-layer topology fingerprint, ratio signals, Root-LD anchor. Full provenance.", "license": "https://creativecommons.org/publicdomain/zero/1.0/", "isAccessibleForFree": true, "creator": { "@type": "Organization", "name": "Boise Standard", "url": "https://boisestandard.org" }, "about": { "@type": "WebSite", "url": "https://www.zeposia.bmshealthcare.jp/", "name": "ゼポジア（潰瘍性大腸炎治療剤）医療関係者向け製品情報サイト | ブリストル・マイヤーズ スクイブ株式会社" }, "variableMeasured": [ { "@type": "PropertyValue", "name": "federationId", "value": "bs-1e5c8c4f" }, { "@type": "PropertyValue", "name": "schemaTypes", "value": "" }, { "@type": "PropertyValue", "name": "schemaCoverageScore", "value": "0.0" }, { "@type": "PropertyValue", "name": "topologyFingerprint", "value": "computed" }, { "@type": "PropertyValue", "name": "topologyModelVersion", "value": "1.0.0" }, { "@type": "PropertyValue", "name": "textLengthCategory", "value": "long" }, { "@type": "PropertyValue", "name": "typeTokenRatio", "value": "0.1549" }, { "@type": "PropertyValue", "name": "nonAsciiRatio", "value": "0.6527" }, { "@type": "PropertyValue", "name": "hapaxLegomenaRatio", "value": "0.1049" }, { "@type": "PropertyValue", "name": "javascriptSurfaceRatio", "value": "0.0" }, { "@type": "PropertyValue", "name": "navRatio", "value": "0.511" }, { "@type": "PropertyValue", "name": "securityLabel", "value": "STRONG" }, { "@type": "PropertyValue", "name": "freshnessLabel", "value": "CURRENT" }, { "@type": "PropertyValue", "name": "interiorPagesCrawled", "value": "22" }, { "@type": "PropertyValue", "name": "mintedAt", "value": "2026-07-11T15:17:49.350843+00:00" }, { "@type": "PropertyValue", "name": "specVersion", "value": "Root-LD v1.0" }, { "@type": "PropertyValue", "name": "entityType", "value": "domain" }, { "@type": "PropertyValue", "name": "detectedLanguage", "value": "ja" }, { "@type": "PropertyValue", "name": "hasGeo", "value": "False" }, { "@type": "PropertyValue", "name": "hasAtomicAnswer", "value": "False" } ], "root_ld": { "anchor": { "uuid": "1e5c8c4f-6e6e-4b55-bf1f-439d5ce2c050", "federation_id": "bs-1e5c8c4f", "sequence": 0, "content_hash": "1a3f64b7827fbe871dc94d805b681ae355b4a9e12b4b3b4b4899e65dfe7cbd8f", "primary_source": "https://www.zeposia.bmshealthcare.jp/", "source_verified": true, "generation_method": "crawl_extract_v1", "spec_version": "1.0", "queued_at": "2026-05-26T20:35:49.688622+00:00", "minted_at": "2026-07-11T15:17:49.350843+00:00" }, "body": { "domain": "zeposia.bmshealthcare.jp", "canonical_url": "https://www.zeposia.bmshealthcare.jp/", "tld": "jp", "slug": "zeposia-bmshealthcare-jp", "status_code": 200, "redirect_chain": [], "response_time_ms": 7113, "ssl_valid": true, "server_header": "Apache", "title": "ゼポジア（潰瘍性大腸炎治療剤）医療関係者向け製品情報サイト | ブリストル・マイヤーズ スクイブ株式会社", "h1": "", "meta_description": "ゼポジア（オザニモド）は、経口投与が可能な中等症から重症の潰瘍性大腸炎を治療するスフィンゴシン1‐リン酸（S1P）受容体調節剤です。本サイトはゼポジアの適正使用を目的とした医療関係者向け製品情報サイトです。", "lang_declared": "ja", "schema_types": [], "schema_score": 0.0, "schema_prop_count": 0, "schema_gap_list": [], "top_semantic_words": [ "true", "north", "ole", "faq", "card", "myers", "bms", "healthcare", "times", "start", "end", "bristol", "squibb", "foot", "note", "heading", "affiliate", "subsidiary", "data", "link", "comp", "secondarynavlink", "asa", "permission", "case", "cookies", "meddra", "med", "colitis", "sandborn", "engl", "vitro", "login", "ulcerative", "creativecommons", "licenses", "pharmacol", "cookie", "pml", "adapted" ], "ratio_signals": { "schema_density": 0.0, "nav_ratio": 0.5111, "content_to_structure_ratio": 0.017246, "external_tld_diversity": 2, "self_declaration_coherence": 0.0769, "schema_to_navigation_alignment": 0.0, "javascript_surface_ratio": 0.0, "url_depth_distribution": { "depth_0": 2, "depth_1": 2, "depth_2": 39, "depth_3plus": 2 } }, "semantic_html_ratio": 0.0, "javascript_surface_ratio": 0.0, "img_alt_coverage": 0.0, "robots_complexity_score": 0, "ariadne_blocked": false, "security_label": "STRONG", "https_enforced": true, "freshness_label": "CURRENT", "tld_starjet_url": "https://boisestandard.org/registry/tld/ledger/jp", "schema_starjet_urls": [], "native_text_sample": "BMS HEALTHCARE\n\nお問い合わせ\n\nリモート面談での情報提供\n\n新規会員登録\n\n製品情報\nゼポジア・臨床成績\n適正使用情報\n動画ライブラリ\nセミナー・講演会\nFAQ\n\n電子化された添付文書\n\nインタビューフォーム\n\nよくあるご質問（FAQ）\n\n予リ\n\n約モ\n\nす｜\n\nるト\n\n　面\n\n　談\n\n　を\n\n最新セミナー・講演会\nゼポジア Webセミナー\n\nDate and Times :\n\n2026.07.17（金）18:45～19:30\n\n演題 :\n\n2026年学会トピックと私のゼポジア体験\n〜⾒えてきた好適患者の姿〜\n\n演者 :\n\n土庫病院 消化器・肛門病センター 副センター⻑\n横尾 貴史 先生\n\nMember only\n\n潰瘍性大腸炎\n\nセミナー・講演会情報はこちら\n\nゼポジアについて\n\nゼポジア電子添文2026年4月改訂（第3版）\n\nゼポジアは、スフィンゴシン1-リン酸（S1P）受容体に結合することで、末梢リンパ組織にリンパ球を保持し、循環血中のリンパ球数を減少させます。\n\n作用機序はこちら\n\n5-アミノサリチル酸（5-ASA）製剤、ステロイド等で、十分な効果が得られず症状", "topology_fingerprint_version": "1.0.0", "entity_type": "domain", "geo": { "address": "", "latitude": null, "longitude": null, "place_id": "", "category": "", "jurisdiction_path": "", "provenance_source": "", "fetched_at": "" }, "atomic_answer": "" }, "recursive": { "edges": [], "appended_at": [], "edge_count": 0 } }, "topology_fingerprint_summary": { "model_version": "1.0.0", "text_length_category": "long", "raw_text_length": 102690, "extracted_text_hash": "942aab5d16777ee7d8f1523d7fa01816fd74d8a63a00ef75404fa57a29543056", "detected_language": "ja", "entity_type": "domain", "type_token_ratio": 0.154881, "non_ascii_ratio": 0.652663, "character_entropy": 5.420062, "hapax_legomena_ratio": 0.104899, "hapax_to_type_ratio": 0.677291, "comma_to_period_ratio": 0.0426, "repetition_score": 0.895101 }, "schema_graph_summary": { "declared_types": [], "parent_types": [], "sibling_types": [], "child_types": [], "negative_space": [ "Action", "BioChemEntity", "CreativeWork", "Event", "Intangible", "MedicalEntity", "Organization", "Person", "Place", "Product" ] } }